08/19 Taiwan BIO Weekly
2025-08-18 |
| Taiwan BIO Weekly |
| Vectorite Biomedical reports H1 revenue up 43 percent YoY, turns loss into profit 15 August, 2025 Vectorite Biomedical (TW: 4170) recently announced its H1 2025 financial results following board approval, reporting revenue up approximately 43 percent year-on-year, with post-tax net profit of around NT$3.83 million, successfully turning profitable after three consecutive years of losses. The company's cell culture technologies are found in 14 hospitals approved under the Special Regulation for Cell Therapy, covering northern, central, and southern Taiwan. It has completed 22 immuno-cell therapy projects, providing DC dendritic cell vaccines and NK natural killer cell products for treating 12 types of stage IV common cancers. More... (in Chinese) |
| Taiwan Bio Therapeutics acquires US firm to boost T-cell drug development 13 August, 2025 Taiwan Bio Therapeutics (TW: 6892) announced that it has signed a merger agreement with its partner US-based TRACT Therapeutics. Taiwan Bio Therapeutics' wholly owned US subsidiary, Taiwan Bio Holding, will acquire 100 percent of TRACT's shares for US$3.5 million in cash, pending necessary approvals from relevant authorities. The company stated that completing the TRACT acquisition marks an important milestone in its strategic plan to enter the US market and become a global leader in cell therapy. More... (in Chinese) |
| US-based Liquidia to present Phase III clinical trial results of Pharmosa Biopharm's pulmonary arterial hypertension therapy 13 August, 2025 New drug developer Pharmosa Biopharm (TW: 6875) licensed its inhaled therapy L606 to US-based pharmaceutical company Liquidia (LQDA) in 2023. At its recent Q2 earnings call, LQDA announced plans to hold an R&D Day in SeptemberŠOctober this year to present the latest results from an open-label Phase III clinical trial of L606 for the treatment of Class I pulmonary arterial hypertension (PAH). The update will include clinical data from patients who have used the drug for up to one year, highlighting its clinical advantages. More... (in Chinese) |
| Primo Biotechnology, Anbogen Therapeutics sign MOU for joint development of precision radioligand therapy 12 August, 2025 Primo Biotechnology, a pioneer in radiopharmaceuticals, has signed an MOU with Anbogen Therapeutics to co-develop and manufacture an innovative precision radioligand therapy for diagnosing and treating solid tumors. Leveraging Primo's expertise in Radioligand Drug Conjugate (RDC) development and end-to-end radiopharmaceutical capabilities, and Anbogen's strengths in targeted delivery and ligand-binding technology, the partnership will apply the PeptideŠDrug Conjugates (PDCs) platform to advance precision oncology. More... (in Chinese) |
| ARC at Sheba Medical Center and [Taiwan's] China Medical University Forge Strategic Partnership in Digital Health Transformation Press release 12 August, 2025 ARC, the global healthcare transformation engine and innovation arm of world-leading hospital Sheba Medical Center, today announced the signing of a Memorandum of Understanding (MOU) with China Medical University (CMU) to establish a strategic partnership for planning a new ARC site within CMU's Biopark. This collaboration will serve as a cornerstone for advancing digital transformation, translational research, and healthcare innovation across Taiwan and the Asia-Pacific region. More... |
| Wearables transform into medical aides: FEMH, ASUS team up for enhanced health assessments 12 August, 2025 The proliferation of smart healthcare is transforming the global landscape, with wearable devices progressively integrating into clinical and health management sectors. The health management center at Far Eastern Memorial Hospital (FEMH) has partnered with ASUS to conduct a strategic experiment, incorporating the ASUS VivoWatch into the advanced health check-up procedure to establish an innovative model of "post-check care." This illustrates the potential of wearable technology in healthcare while providing essential practical experience for the sector. More... |
| Medeon Biodesign's thoracic aortic repair device receives US FDA approval for Phase II clinical trial 12 August, 2025 Medeon Biodesign (TW: 6499) announced that its subsidiary, Aquedeon Medical, has received US FDA approval to initiate a Phase II pivotal clinical trial for its thoracic aortic repair device, Duett. Including 35 cases previously approved, the trial will enroll a total of 72 to 90 patients. The aim is to validate Duett's clinical value on a larger scale, taking another critical step toward FDA market approval. Medeon Biodesign stated that open aortic repair is the gold standard for treating aortic dissection and aneurysm, with ascending aorta cases making up about 70 percent of all cases. The surgery is highly challenging, requiring manual suturing of a synthetic graft to three brain-bound branches under deep hypothermic circulatory arrest (DHCA). Even top surgeons take 30Š45 minutes, but exceeding 40 minutes greatly increases stroke and neurological risks. Using proprietary vascular anastomosis technology, Duett can cut suturing time by over 90%, easing the burden on surgeons and patients. More... (in Chinese) |
| Advagene Biopharma's new asthma drug receives TFDA approval to conduct Phase II clinical trial 11 August, 2025 Advagene Biopharma (TW: 6709) announced that it has received approval from the Taiwan Food and Drug Administration (TFDA) to conduct a Phase II clinical trial of its new asthma drug AD17002 for the treatment of moderate to severe eosinophilic asthma. More... (in Chinese) |
| ITRI teams up with PharmaEssentia to tap into the cancer immunotherapy market 11 August, 2025 ITRI announced today that it is entering into a strategic collaboration with PharmaEssentia to advance the development of ITRI-501, a novel anti-T-cell immunoglobulin and ITIM domain (TIGIT) immune checkpoint antibody. The partnership aims to move this innovative technology from the laboratory to clinical applications, accelerating the commercialization of the new drug. More... (in Chinese) |
| Foresee Pharmaceuticals' Camcevi three-month formulation targeting approval for US market 10 August, 2025 Foresee Pharmaceuticals (TW: 6576) recently announced its consolidated revenue for July was approximately NT$8.85 million, a decrease of 77.2 percent month-on-month and 75.2 percent year-on-year. This was mainly due to no shipments to distributors in July and changes in the distributors' customer mix during the month. Looking ahead to the second half of the year, Foresee Pharmaceuticals' three-month formulation of Camcevi is targeting marketing approval in the US on August 29. With milestone payments, Foresee's revenue is expected to show significant growth compared to the same period last year. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |